CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Finally, we think that the choice of peripheral blood stem/progenitor cell donor samples as the control is more suitable than bone marrow or cord blood leukocytes when assessing gene expression changes in circulating CP-CML CD34+ cells.